UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.579

Sortiert nach

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Annals of oncology, 2014-11, Vol.25 (11), p.2211-2217

2014

Volltextzugriff (PDF)

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

Annals of oncology, 2013-02, Vol.24 (2), p.441-448

2013

Volltextzugriff (PDF)

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

Bone marrow transplantation (Basingstoke), 2014-02, Vol.49 (2), p.185-189

2014

Volltextzugriff (PDF)

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Annals of oncology, 2018-08, Vol.29 (8), p.1822-1827

2018

Volltextzugriff (PDF)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of oncology, 2018-09, Vol.29 (9), p.1932-1938

2018

Volltextzugriff (PDF)

Unmet needs in the first-line treatment of follicular lymphoma

Annals of oncology, 2017-09, Vol.28 (9), p.2094-2106

2017

Volltextzugriff (PDF)

Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow

Expert review of anticancer therapy, 2017-03, Vol.17 (3), p.271-279

2017

Volltextzugriff (PDF)

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

British journal of haematology, 2020-12, Vol.191 (5), p.806-815

2020

Volltextzugriff (PDF)

Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks

Epidemiology and infection, 2009-09, Vol.137 (9), p.1323-1332

2009

Volltextzugriff (PDF)

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study

Annals of oncology, 2015-11, Vol.26 (11), p.2311-2317

2015

Volltextzugriff (PDF)

Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.167-168

2023

Volltextzugriff (PDF)

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.119-121

2023

Volltextzugriff (PDF)

Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes

Hematological oncology, 2023-06, Vol.41 (S2), p.430-432

2023

Volltextzugriff (PDF)

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype

Oncogene, 2017-07, Vol.36 (29), p.4224-4232

2017

Volltextzugriff (PDF)

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.175-177

2023

Volltextzugriff (PDF)

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY

Hematological oncology, 2023-06, Vol.41 (S2), p.223-225

2023

Volltextzugriff (PDF)

The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era

Leukemia & lymphoma, 2016-08, Vol.57 (8), p.1876-1882

2016

Volltextzugriff (PDF)

PB2109: REALMIND: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA STARTING SECOND/THIRD‐LINE THERAPY AND NOT RECEIVING A STEM CELL TRANSPLANT

HemaSphere, 2022-06, Vol.6 (Suppl), p.1980-1981

2022

Volltextzugriff (PDF)

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

Bone marrow transplantation (Basingstoke), 2017-01, Vol.52 (1), p.132-134

2017

Volltextzugriff (PDF)

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2022-01, Vol.386 (4), p.351-363

2022

Volltextzugriff (PDF)

Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

Journal of the National Cancer Institute. Monographs, 2014-08, Vol.2014 (48), p.76-86

2014

Volltextzugriff (PDF)

Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma

CA: a cancer journal for clinicians, 2010-11, Vol.60 (6), p.393-408

2010

Volltextzugriff (PDF)

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Hematological oncology, 2023-06, Vol.41, p.119-121

2023

Volltextzugriff (PDF)

Clinical investigators as critical determinants in pharmaceutical innovation

Nature medicine, 1997-02, Vol.3 (2), p.136-143

1997

Volltextzugriff (PDF)

1 – 25 von 1.579

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.439)
Mit Volltextzugriff
(1.484)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(769)
Life Sciences & Biomedicine
(447)
Physics
(413)
Humans
(400)
Hadron-Hadron Scattering
(318)
Physics Of Elementary Particles And Fields
(312)
Physical Sciences
(286)
Elementary Particles
(261)
Quantum Field Theories
(259)
Quantum Field Theory
(259)
String Theory
(259)
Physics And Astronomy
(257)
Regular Article - Experimental Physics
(242)
Female
(236)
Luminosity
(218)
Male
(212)
Classical And Quantum Gravitation
(210)
Quantum Physics
(210)
Relativity Theory
(210)
Adult
(203)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Unmet needs in the first-line treatment of follicular lymphoma

Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study

Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY

The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era

PB2109: REALMIND: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA STARTING SECOND/THIRD‐LINE THERAPY AND NOT RECEIVING A STEM CELL TRANSPLANT

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Clinical investigators as critical determinants in pharmaceutical innovation

Suchergebnisse filtern